View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsReata Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Reata Pharmaceuticals 의 수입은 연평균 -17.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 44.5%의 비율로 감소해 왔습니다.핵심 정보-17.31%순이익 성장률-12.57%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-44.48%자기자본이익률-100.38%순이익률-373.18%최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$5.12 (up from US$2.02 loss in 2Q 2022). Revenue: US$22.7m (up US$22.0m from 2Q 2022). Net income: US$193.0m (up US$266.6m from 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 17% per year.Reported Earnings • May 10First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$3.14 loss per share (further deteriorated from US$2.03 loss in 1Q 2022). Net loss: US$116.1m (loss widened 57% from 1Q 2022). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$8.54 loss per share (further deteriorated from US$8.19 loss in FY 2021). Net loss: US$311.9m (loss widened 4.9% from FY 2021). Products in clinical trials Phase I: 1 Phase III: 3 Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 1.3%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 10Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: US$2.16 loss per share (further deteriorated from US$1.97 loss in 3Q 2021). Net loss: US$79.0m (loss widened 10.0% from 3Q 2021). Revenue missed analyst estimates by 26%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 08Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: US$2.02 loss per share (down from US$2.00 loss in 2Q 2021). Revenue: US$762.0k (down 66% from 2Q 2021). Net loss: US$73.6m (loss widened 1.2% from 2Q 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 199%, compared to a 14% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 10First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: US$2.03 loss per share (down from US$1.86 loss in 1Q 2021). Revenue: US$914.0k (down 3.2% from 1Q 2021). Net loss: US$73.8m (loss widened 9.5% from 1Q 2021). Revenue missed analyst estimates by 41%. Earnings per share (EPS) exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 54%, compared to a 6.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updates공시 • Sep 28Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from NASDAQ Composite IndexReata Pharmaceuticals, Inc. has been removed from Nasdaq Composite Index.공시 • Sep 27+ 3 more updatesBiogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from a group of shareholders for approximately $6.8 billion on July 28, 2023. Biogen has agreed to acquire Reata for $172.50 per share in cash. The acquisition of Reata is expected to be slightly dilutive to Biogen’s Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs. Biogen expects to finance the acquisition with cash on hand, supplemented by the issuance of term debt. JPMorgan Chase Bank, N.A. has committed to provide a 364-day senior unsecured bridge loan facility in an aggregate principal amount of up to $1.5 billion to fund the transaction. In case of termination of the transaction under certain circumstances, Reata will be required to pay Biogen a termination fee equal to $264 million. In case of termination of the transaction under certain circumstances, Biogen will be required to pay Reata a termination fee equal to $301 million. Daniel R. Kay and Michael R. Isby of Simpson Thacher & Bartlett LLP acted as legal advisor to JPMorgan Chase Bank, N.A. As of September 21, 2023, shareholders of Reata Pharmaceuticals, Inc. approved the merger. The transaction is expected to close on September 26, 2023. The transaction is subject to customary closing conditions, including approval by Reata stockholders, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act of 1976, and the receipt of necessary regulatory approvals. Biogen has entered into voting and support agreements with certain stockholders of Reata representing approximately 36% of the voting power of Reata’s common stock. The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the Merger expired at 11:59 p.m. Eastern Time on September 11, 2023. The transaction, which was unanimously approved by the boards of directors of both companies, is currently anticipated to close in the fourth quarter of 2023. Biogen expects this acquisition to be accounted for as a business combination. Lazard acted as financial advisor to Biogen in this transaction and Faiza Saeed; Mark Greene; Aaron Gruber and Bethany Pfalzgraf of Cravath, Swaine & Moore acted as its legal advisor. Goldman Sachs & Co. LLC acted as financial advisor and fairness opinion provider to to Reata and Lande Spottswood, David Peck, Shane Tucker, Sean Becker, Kara Kuritz, Rick Sofield, Sarah Mitchell, Hill Wellford, Brian Russell, Robert Kimball and Katherine Frank of Vinson & Elkins acted as its legal advisor. Christopher M Barlow and Paul Schnell of Skadden, Arps, Slate, Meagher & Flom LLP represented Goldman Sachs & Co. LLC as financial advisor to Reata Pharmaceuticals, Inc. D.F. King & Co., Inc. acted as proxy solicitor to Reata, and will receive a fee of $20,000 for its services. Reata has agreed to pay Goldman Sachs a transaction fee of approximately $77 million, all of which is contingent upon consummation of the merger. Equiniti Trust Company LLC acted as transfer agent to Reata. Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) on September 26, 2023. The acquisition of Reata is expected to be slightly dilutive to Biogen’s Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs. As a result of the transaction closing, Reata’s Class A common stock will no longer be listed for trading on the Nasdaq Global Market.Recent Insider Transactions • Sep 19Insider recently sold US$546k worth of stockOn the 14th of September, Andrea Loewen-Rodriguez sold around 3k shares on-market at roughly US$172 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$15m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Sep 17Insider notifies of intention to sell stockAndrea Loewen-Rodriguez intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of September. If the sale is conducted around the recent share price of US$172, it would amount to US$546k. Since March 2023, Andrea's direct individual holding has decreased from 5.49k shares to 0. Company insiders have collectively sold US$61m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Aug 18Executive VP & Chief Innovation Officer recently sold US$463k worth of stockOn the 16th of August, Colin Meyer sold around 3k shares on-market at roughly US$169 per share. This transaction amounted to 3.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$6.0m. Insiders have been net sellers, collectively disposing of US$14m more than they bought in the last 12 months.공시 • Aug 17Sanofi Reportedly Second Bidder for ReataBiogen Inc. (NasdaqGS:BIIB) narrowly beat out Sanofi (ENXTPA:SAN) to clinch its $7.3 billion acquisition of Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), according to people familiar with the matter. An entity identified as “Party A” in a regulatory filing Friday lost the competition for Reata by 50 cents per share after several rounds of bidding. Party A was Sanofi, the people said, asking to not be identified because the matter isn’t public. Representatives for Reata, Sanofi and Biogen declined to comment.Major Estimate Revision • Aug 17Consensus revenue estimates increase by 60%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$55.8m to US$89.3m. Forecast losses expected to reduce from -US$10.43 to -US$2.51 per share. Pharmaceuticals industry in the US expected to see average net income growth of 4.2% next year. Consensus price target of US$172 unchanged from last update. Share price was steady at US$169 over the past week.Major Estimate Revision • Aug 15Consensus revenue estimates increase by 67%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$55.8m to US$93.2m. Forecast losses expected to reduce from -US$10.43 to -US$2.28 per share. Pharmaceuticals industry in the US expected to see average net income growth of 5.9% next year. Consensus price target of US$172 unchanged from last update. Share price was steady at US$169 over the past week.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$5.12 (up from US$2.02 loss in 2Q 2022). Revenue: US$22.7m (up US$22.0m from 2Q 2022). Net income: US$193.0m (up US$266.6m from 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 17% per year.Recent Insider Transactions Derivative • Jul 31COO, CFO & President notifies of intention to sell stockManmeet Soni intends to sell 38k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of July. If the sale is conducted around the recent share price of US$109, it would amount to US$4.1m. Since March 2023, Manmeet's direct individual holding has decreased from 28.76k shares to 8.05k. Company insiders have collectively sold US$40m more than they bought, via options and on-market transactions in the last 12 months.New Risk • Jul 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$131m). Minor Risks Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Significant insider selling over the past 3 months (US$9.4m sold). Revenue is less than US$5m (US$1.5m revenue).공시 • Jul 29Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion on July 28, 2023. Biogen has agreed to acquire Reata for $172.50 per share in cash. The acquisition of Reata is expected to be slightly dilutive to Biogen’s Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs. Biogen expects to finance the acquisition with cash on hand, supplemented by the issuance of term debt. The transaction is subject to customary closing conditions, including approval by Reata stockholders and the receipt of necessary regulatory approvals. Biogen has entered into voting and support agreements with certain stockholders of Reata representing approximately 36% of the voting power of Reata’s common stock. The transaction, which was approved by the boards of directors of both companies, is currently anticipated to close in the fourth quarter of 2023. Biogen expects this acquisition to be accounted for as a business combination. Lazard acted as financial advisor to Biogen in this transaction and Cravath, Swaine & Moore acted as its legal advisor. Goldman Sachs acted as financial advisor to Reata and Vinson & Elkins acted as its legal advisor.Price Target Changed • Jul 28Price target increased by 8.5% to US$125Up from US$115, the current price target is an average from 10 analysts. New target price is 25% below last closing price of US$167. Stock is up 445% over the past year. The company is forecast to post a net loss per share of US$10.49 next year compared to a net loss per share of US$8.54 last year.공시 • Jun 28Reata Pharmaceuticals, Inc. Announces Approval of Prior Approval Supplement for SKYCLARYS®? (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's AtaxiaReata Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS®? (omaveloxolone), the first and only FDA approved drug for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. With the approval of the PAS, SKYCLARYS is now available to patients with Friedreich's ataxIA in the United States. SKYCLARYS®®? (omaveloxalone) is an oral, once-daily medication indicated for the treatment of Friedrech's ataxia in adults, adolescents aged 16 years and older in the United States. The Company's Marketing Authorization Application for omaveloxolone is under review in Europe by the European Medicines Agency (EMA). The European Commission has granted Orphan Drug designation in Europe to omaveloxolone for the treatment of FriedreICH's ataxia. Hormonal Contrace contraceptive: Counsel females to use an alternative contraceptive method (e.g., non-hormonal intrarauterine system) or additional non-hormonal contraceptive (e.g., condoms) during concomitant use and for 28 days after discontinuation of SKYCLARYS. This is not a complete list of potential drug interactions. Specific Population: Due to the uncertainty of any potential adverse effects on the breastfed infant, women are advised not to breastfeed during treatment with SKYCLARYS.공시 • Jun 25Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth IndexReata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth IndexRecent Insider Transactions • Jun 18COO, CFO & President recently sold US$6.0m worth of stockOn the 13th of June, Manmeet Soni sold around 58k shares on-market at roughly US$104 per share. This transaction amounted to 94% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Manmeet has been a net seller over the last 12 months, reducing personal holdings by US$8.2m.Recent Insider Transactions Derivative • Jun 16COO, CFO & President notifies of intention to sell stockManmeet Soni intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$99.62, it would amount to US$469k. Since March 2023, Manmeet's direct individual holding has increased from 28.76k shares to 61.22k. Company insiders have collectively sold US$32m more than they bought, via options and on-market transactions in the last 12 months.공시 • Jun 14Reata Pharmaceuticals Appoints Rajiv Patni as Executive Vice President, Chief Research & Development OfficerReata Pharmaceuticals, Inc. announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company’s research and development functions. Dr. Patni brings over 23 years of global product development experience, including 18 clinical programs in the cardiology, diabetology, hepatology, neurology, and benign hematology therapeutic areas. Prior to joining Reata, Dr. Patni was Chief Medical Officer (CMO) at Global Blood Therapeutics from 2020 to 2023. Prior to that time, he was CMO at Portola Pharmaceuticals and Adamas Pharmaceuticals. Early in his career, Dr. Patni worked at Pfizer, Roche, and Actelion, where he held positions of increasing responsibility. His proven track record in fostering successful team efforts at these different companies contributed to the approval of 10 medicines from the U.S. Food and Drug Administration, European Medicines Agency, and other regulatory agencies. Dr. Patni received his MD degree from the Mount Sinai School of Medicine in New York City, as part of an accelerated BS/MD program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician before joining industry.Recent Insider Transactions • May 18Insider recently sold US$616k worth of stockOn the 16th of May, Andrea Loewen-Rodriguez sold around 7k shares on-market at roughly US$86.01 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$808k. Insiders have been net sellers, collectively disposing of US$4.6m more than they bought in the last 12 months.Major Estimate Revision • May 17Consensus revenue estimates increase by 27%, EPS downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$42.5m to US$53.9m. EPS estimate fell from -US$8.95 to -US$10.28 per share. Pharmaceuticals industry in the US expected to see average net income decline 7.8% next year. Consensus price target broadly unchanged at US$113. Share price fell 19% to US$85.02 over the past week.Breakeven Date Change • May 12Forecast to breakeven in 2025The 9 analysts covering Reata Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 26% per year to 2024. The company is expected to make a profit of US$190.1m in 2025. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Reported Earnings • May 10First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$3.14 loss per share (further deteriorated from US$2.03 loss in 1Q 2022). Net loss: US$116.1m (loss widened 57% from 1Q 2022). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Mar 20Executive VP & Chief Commercial Officer recently sold US$808k worth of stockOn the 13th of March, Dawn Bir sold around 9k shares on-market at roughly US$86.77 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.9m more than they bought in the last 12 months.Recent Insider Transactions • Mar 16Executive VP & Chief Commercial Officer recently sold US$630k worth of stockOn the 7th of March, Dawn Bir sold around 7k shares on-market at roughly US$90.03 per share. This transaction amounted to 92% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.1m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Mar 09Executive VP & Chief Innovation Officer exercised options and sold US$7.7m worth of stockOn the 2nd of March, Colin Meyer exercised options to acquire 89k shares at no cost and sold these for an average price of US$86.69 per share. This trade did not impact their existing holding. Since June 2022, Colin's direct individual holding has increased from 93.49k shares to 101.33k. Company insiders have collectively sold US$17m more than they bought, via options and on-market transactions in the last 12 months.Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 9 analysts covering Reata Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 26% per year to 2024. The company is expected to make a profit of US$104.6m in 2025. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 03Consensus revenue estimates increase by 18%, EPS downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$26.1m to US$30.8m. EPS estimate fell from -US$8.43 to -US$9.00 per share. Pharmaceuticals industry in the US expected to see average net income growth of 5.6% next year. Consensus price target up from US$62.40 to US$111. Share price rose 95% to US$86.81 over the past week.Price Target Changed • Mar 01Price target increased by 75% to US$104Up from US$59.50, the current price target is an average from 10 analysts. New target price is 12% above last closing price of US$93.17. Stock is up 184% over the past year. The company is forecast to post a net loss per share of US$8.65 next year compared to a net loss per share of US$8.54 last year.Reported Earnings • Feb 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$8.54 loss per share (further deteriorated from US$8.19 loss in FY 2021). Net loss: US$311.9m (loss widened 4.9% from FY 2021). Products in clinical trials Phase I: 1 Phase III: 3 Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 1.3%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target increased to US$59.50Up from US$54.20, the current price target is an average from 10 analysts. New target price is 43% above last closing price of US$41.67. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$8.43 next year compared to a net loss per share of US$8.19 last year.Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$3.01m to US$2.59m. EPS estimate unchanged at -US$8.43 per share. Pharmaceuticals industry in the US expected to see average net income growth of 4.6% next year. Consensus price target up from US$54.20 to US$59.50. Share price rose 3.4% to US$41.67 over the past week.Price Target Changed • Nov 11Price target increased to US$59.50Up from US$54.20, the current price target is an average from 10 analysts. New target price is 55% above last closing price of US$38.27. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$8.43 next year compared to a net loss per share of US$8.19 last year.Reported Earnings • Nov 10Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: US$2.16 loss per share (further deteriorated from US$1.97 loss in 3Q 2021). Net loss: US$79.0m (loss widened 10.0% from 3Q 2021). Revenue missed analyst estimates by 26%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 13FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drugReata Pharmaceuticals (NASDAQ:RETA) on Thursday said the U.S. FDA had informed the company that it was not planning to hold an advisory committee meeting for the review of its new drug application for its Friedreich's ataxia treatment. The company is developing an investigational activator called omaveloxolone for the treatment of the rare, genetic neuromuscular disorder. The treatment has previously received U.S. FDA orphan drug, fast track and rare pediatric disease designations. Class A shares of RETA earlier closed +2.6% at $25.05.Major Estimate Revision • Aug 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$4.26m to US$3.18m. EPS estimate unchanged at -US$8.43 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.6% next year. Consensus price target down from US$57.11 to US$50.67. Share price fell 14% to US$20.61 over the past week.Price Target Changed • Aug 10Price target decreased to US$50.67Down from US$57.11, the current price target is an average from 5 analysts. New target price is 135% above last closing price of US$21.56. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$8.45 next year compared to a net loss per share of US$8.19 last year.Reported Earnings • Aug 08Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: US$2.02 loss per share (down from US$2.00 loss in 2Q 2021). Revenue: US$762.0k (down 66% from 2Q 2021). Net loss: US$73.6m (loss widened 1.2% from 2Q 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 199%, compared to a 14% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Aug 05Reata Pharmaceuticals Q2 2022 Earnings PreviewReata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$1.97 (-49.2% Y/Y) and the consensus Revenue Estimate is $1.46M (-34.2% Y/Y). Over the last 2 years, RETA has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.Major Estimate Revision • May 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$5.27m to US$4.74m. EPS estimate increased from -US$8.95 to -US$8.44 per share. Pharmaceuticals industry in the US expected to see average net income growth of 12% next year. Consensus price target broadly unchanged at US$59.00. Share price rose 14% to US$27.84 over the past week.Reported Earnings • May 10First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: US$2.03 loss per share (down from US$1.86 loss in 1Q 2021). Revenue: US$914.0k (down 3.2% from 1Q 2021). Net loss: US$73.8m (loss widened 9.5% from 1Q 2021). Revenue missed analyst estimates by 41%. Earnings per share (EPS) exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 54%, compared to a 6.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.Price Target Changed • Apr 27Price target increased to US$59.67Up from US$53.33, the current price target is an average from 8 analysts. New target price is 130% above last closing price of US$25.91. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$8.95 next year compared to a net loss per share of US$8.19 last year.Seeking Alpha • Mar 28Reata Pharmaceuticals: Once Beaten, Twice ShyReata's lead asset, bardoxolone, is beyond salvage. Omaveloxolone, the second asset, may be producing hope in some investors. However, I would be very careful about what Reata tells us about what the FDA told Reata.Price Target Changed • Mar 24Price target increased to US$62.75Up from US$53.67, the current price target is an average from 7 analysts. New target price is 69% above last closing price of US$37.09. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$8.91 next year compared to a net loss per share of US$8.19 last year.Reported Earnings • Mar 02Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$8.19 loss per share (down from US$7.35 loss in FY 2020). Revenue: US$11.5m (up 27% from FY 2020). Net loss: US$297.4m (loss widened 20% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 1.1%. Over the next year, revenue is expected to shrink by 48% compared to a 21% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Mar 01No longer forecast to breakevenThe 7 analysts covering Reata Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$65.4m in 2024. New consensus forecast suggests the company will make a loss of US$378.9m in 2024.Seeking Alpha • Dec 31Reata's Advisory Committee Hiccup Ruins Its Future ProspectsReata's bardoxolone was unanimously turned down by an advisory committee panel, voting 13-0 against the drug. Management's characterisation of FDA interactions raises concerns about the company. I will stay cautious around this ticker.매출 및 비용 세부 내역Reata Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:RETA 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 2323-88160031 Mar 231-354139031 Dec 222-312109030 Sep 223-312108030 Jun 2210-305106031 Mar 2211-304103031 Dec 2111-29799030 Sep 2114-27888030 Jun 218-27180031 Mar 219-26675031 Dec 209-24875030 Sep 208-36978030 Jun 2015-34374031 Mar 2020-31069031 Dec 1927-29058030 Sep 1932-12944030 Jun 1930-12037031 Mar 1929-11436031 Dec 1854-8133030 Sep 1855-7231030 Jun 1862-5329031 Mar 1867-3625031 Dec 1748-4823030 Sep 1750-3522030 Jun 1750-2420031 Mar 1750-1319031 Dec 1650-617030 Sep 1650-416030 Jun 1650-215031 Mar 1650-314031 Dec 1550-114030 Sep 1550013-2530 Jun 1551012031 Mar 1551212031 Dec 1451112031 Dec 1351-361240양질의 수익: RETA 은(는) 현재 수익성이 없습니다.이익 마진 증가: RETA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RETA은 수익성이 없으며 지난 5년 동안 손실이 연평균 17.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RETA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RETA은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RETA는 현재 수익성이 없으므로 자본 수익률이 음수(-100.38%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/09/27 11:19종가2023/09/25 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Reata Pharmaceuticals, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Brian SkorneyBairdDae Gon HaBTIGCharles DuncanCantor Fitzgerald & Co.9명의 분석가 더 보기
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$5.12 (up from US$2.02 loss in 2Q 2022). Revenue: US$22.7m (up US$22.0m from 2Q 2022). Net income: US$193.0m (up US$266.6m from 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 17% per year.
Reported Earnings • May 10First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$3.14 loss per share (further deteriorated from US$2.03 loss in 1Q 2022). Net loss: US$116.1m (loss widened 57% from 1Q 2022). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$8.54 loss per share (further deteriorated from US$8.19 loss in FY 2021). Net loss: US$311.9m (loss widened 4.9% from FY 2021). Products in clinical trials Phase I: 1 Phase III: 3 Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 1.3%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 10Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: US$2.16 loss per share (further deteriorated from US$1.97 loss in 3Q 2021). Net loss: US$79.0m (loss widened 10.0% from 3Q 2021). Revenue missed analyst estimates by 26%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 08Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: US$2.02 loss per share (down from US$2.00 loss in 2Q 2021). Revenue: US$762.0k (down 66% from 2Q 2021). Net loss: US$73.6m (loss widened 1.2% from 2Q 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 199%, compared to a 14% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 10First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: US$2.03 loss per share (down from US$1.86 loss in 1Q 2021). Revenue: US$914.0k (down 3.2% from 1Q 2021). Net loss: US$73.8m (loss widened 9.5% from 1Q 2021). Revenue missed analyst estimates by 41%. Earnings per share (EPS) exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 54%, compared to a 6.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
공시 • Sep 28Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from NASDAQ Composite IndexReata Pharmaceuticals, Inc. has been removed from Nasdaq Composite Index.
공시 • Sep 27+ 3 more updatesBiogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from a group of shareholders for approximately $6.8 billion on July 28, 2023. Biogen has agreed to acquire Reata for $172.50 per share in cash. The acquisition of Reata is expected to be slightly dilutive to Biogen’s Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs. Biogen expects to finance the acquisition with cash on hand, supplemented by the issuance of term debt. JPMorgan Chase Bank, N.A. has committed to provide a 364-day senior unsecured bridge loan facility in an aggregate principal amount of up to $1.5 billion to fund the transaction. In case of termination of the transaction under certain circumstances, Reata will be required to pay Biogen a termination fee equal to $264 million. In case of termination of the transaction under certain circumstances, Biogen will be required to pay Reata a termination fee equal to $301 million. Daniel R. Kay and Michael R. Isby of Simpson Thacher & Bartlett LLP acted as legal advisor to JPMorgan Chase Bank, N.A. As of September 21, 2023, shareholders of Reata Pharmaceuticals, Inc. approved the merger. The transaction is expected to close on September 26, 2023. The transaction is subject to customary closing conditions, including approval by Reata stockholders, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act of 1976, and the receipt of necessary regulatory approvals. Biogen has entered into voting and support agreements with certain stockholders of Reata representing approximately 36% of the voting power of Reata’s common stock. The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the Merger expired at 11:59 p.m. Eastern Time on September 11, 2023. The transaction, which was unanimously approved by the boards of directors of both companies, is currently anticipated to close in the fourth quarter of 2023. Biogen expects this acquisition to be accounted for as a business combination. Lazard acted as financial advisor to Biogen in this transaction and Faiza Saeed; Mark Greene; Aaron Gruber and Bethany Pfalzgraf of Cravath, Swaine & Moore acted as its legal advisor. Goldman Sachs & Co. LLC acted as financial advisor and fairness opinion provider to to Reata and Lande Spottswood, David Peck, Shane Tucker, Sean Becker, Kara Kuritz, Rick Sofield, Sarah Mitchell, Hill Wellford, Brian Russell, Robert Kimball and Katherine Frank of Vinson & Elkins acted as its legal advisor. Christopher M Barlow and Paul Schnell of Skadden, Arps, Slate, Meagher & Flom LLP represented Goldman Sachs & Co. LLC as financial advisor to Reata Pharmaceuticals, Inc. D.F. King & Co., Inc. acted as proxy solicitor to Reata, and will receive a fee of $20,000 for its services. Reata has agreed to pay Goldman Sachs a transaction fee of approximately $77 million, all of which is contingent upon consummation of the merger. Equiniti Trust Company LLC acted as transfer agent to Reata. Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) on September 26, 2023. The acquisition of Reata is expected to be slightly dilutive to Biogen’s Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs. As a result of the transaction closing, Reata’s Class A common stock will no longer be listed for trading on the Nasdaq Global Market.
Recent Insider Transactions • Sep 19Insider recently sold US$546k worth of stockOn the 14th of September, Andrea Loewen-Rodriguez sold around 3k shares on-market at roughly US$172 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$15m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Sep 17Insider notifies of intention to sell stockAndrea Loewen-Rodriguez intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of September. If the sale is conducted around the recent share price of US$172, it would amount to US$546k. Since March 2023, Andrea's direct individual holding has decreased from 5.49k shares to 0. Company insiders have collectively sold US$61m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Aug 18Executive VP & Chief Innovation Officer recently sold US$463k worth of stockOn the 16th of August, Colin Meyer sold around 3k shares on-market at roughly US$169 per share. This transaction amounted to 3.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$6.0m. Insiders have been net sellers, collectively disposing of US$14m more than they bought in the last 12 months.
공시 • Aug 17Sanofi Reportedly Second Bidder for ReataBiogen Inc. (NasdaqGS:BIIB) narrowly beat out Sanofi (ENXTPA:SAN) to clinch its $7.3 billion acquisition of Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), according to people familiar with the matter. An entity identified as “Party A” in a regulatory filing Friday lost the competition for Reata by 50 cents per share after several rounds of bidding. Party A was Sanofi, the people said, asking to not be identified because the matter isn’t public. Representatives for Reata, Sanofi and Biogen declined to comment.
Major Estimate Revision • Aug 17Consensus revenue estimates increase by 60%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$55.8m to US$89.3m. Forecast losses expected to reduce from -US$10.43 to -US$2.51 per share. Pharmaceuticals industry in the US expected to see average net income growth of 4.2% next year. Consensus price target of US$172 unchanged from last update. Share price was steady at US$169 over the past week.
Major Estimate Revision • Aug 15Consensus revenue estimates increase by 67%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$55.8m to US$93.2m. Forecast losses expected to reduce from -US$10.43 to -US$2.28 per share. Pharmaceuticals industry in the US expected to see average net income growth of 5.9% next year. Consensus price target of US$172 unchanged from last update. Share price was steady at US$169 over the past week.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$5.12 (up from US$2.02 loss in 2Q 2022). Revenue: US$22.7m (up US$22.0m from 2Q 2022). Net income: US$193.0m (up US$266.6m from 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 17% per year.
Recent Insider Transactions Derivative • Jul 31COO, CFO & President notifies of intention to sell stockManmeet Soni intends to sell 38k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of July. If the sale is conducted around the recent share price of US$109, it would amount to US$4.1m. Since March 2023, Manmeet's direct individual holding has decreased from 28.76k shares to 8.05k. Company insiders have collectively sold US$40m more than they bought, via options and on-market transactions in the last 12 months.
New Risk • Jul 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$131m). Minor Risks Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Significant insider selling over the past 3 months (US$9.4m sold). Revenue is less than US$5m (US$1.5m revenue).
공시 • Jul 29Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion on July 28, 2023. Biogen has agreed to acquire Reata for $172.50 per share in cash. The acquisition of Reata is expected to be slightly dilutive to Biogen’s Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs. Biogen expects to finance the acquisition with cash on hand, supplemented by the issuance of term debt. The transaction is subject to customary closing conditions, including approval by Reata stockholders and the receipt of necessary regulatory approvals. Biogen has entered into voting and support agreements with certain stockholders of Reata representing approximately 36% of the voting power of Reata’s common stock. The transaction, which was approved by the boards of directors of both companies, is currently anticipated to close in the fourth quarter of 2023. Biogen expects this acquisition to be accounted for as a business combination. Lazard acted as financial advisor to Biogen in this transaction and Cravath, Swaine & Moore acted as its legal advisor. Goldman Sachs acted as financial advisor to Reata and Vinson & Elkins acted as its legal advisor.
Price Target Changed • Jul 28Price target increased by 8.5% to US$125Up from US$115, the current price target is an average from 10 analysts. New target price is 25% below last closing price of US$167. Stock is up 445% over the past year. The company is forecast to post a net loss per share of US$10.49 next year compared to a net loss per share of US$8.54 last year.
공시 • Jun 28Reata Pharmaceuticals, Inc. Announces Approval of Prior Approval Supplement for SKYCLARYS®? (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's AtaxiaReata Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS®? (omaveloxolone), the first and only FDA approved drug for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. With the approval of the PAS, SKYCLARYS is now available to patients with Friedreich's ataxIA in the United States. SKYCLARYS®®? (omaveloxalone) is an oral, once-daily medication indicated for the treatment of Friedrech's ataxia in adults, adolescents aged 16 years and older in the United States. The Company's Marketing Authorization Application for omaveloxolone is under review in Europe by the European Medicines Agency (EMA). The European Commission has granted Orphan Drug designation in Europe to omaveloxolone for the treatment of FriedreICH's ataxia. Hormonal Contrace contraceptive: Counsel females to use an alternative contraceptive method (e.g., non-hormonal intrarauterine system) or additional non-hormonal contraceptive (e.g., condoms) during concomitant use and for 28 days after discontinuation of SKYCLARYS. This is not a complete list of potential drug interactions. Specific Population: Due to the uncertainty of any potential adverse effects on the breastfed infant, women are advised not to breastfeed during treatment with SKYCLARYS.
공시 • Jun 25Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth IndexReata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth Index
Recent Insider Transactions • Jun 18COO, CFO & President recently sold US$6.0m worth of stockOn the 13th of June, Manmeet Soni sold around 58k shares on-market at roughly US$104 per share. This transaction amounted to 94% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Manmeet has been a net seller over the last 12 months, reducing personal holdings by US$8.2m.
Recent Insider Transactions Derivative • Jun 16COO, CFO & President notifies of intention to sell stockManmeet Soni intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$99.62, it would amount to US$469k. Since March 2023, Manmeet's direct individual holding has increased from 28.76k shares to 61.22k. Company insiders have collectively sold US$32m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Jun 14Reata Pharmaceuticals Appoints Rajiv Patni as Executive Vice President, Chief Research & Development OfficerReata Pharmaceuticals, Inc. announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company’s research and development functions. Dr. Patni brings over 23 years of global product development experience, including 18 clinical programs in the cardiology, diabetology, hepatology, neurology, and benign hematology therapeutic areas. Prior to joining Reata, Dr. Patni was Chief Medical Officer (CMO) at Global Blood Therapeutics from 2020 to 2023. Prior to that time, he was CMO at Portola Pharmaceuticals and Adamas Pharmaceuticals. Early in his career, Dr. Patni worked at Pfizer, Roche, and Actelion, where he held positions of increasing responsibility. His proven track record in fostering successful team efforts at these different companies contributed to the approval of 10 medicines from the U.S. Food and Drug Administration, European Medicines Agency, and other regulatory agencies. Dr. Patni received his MD degree from the Mount Sinai School of Medicine in New York City, as part of an accelerated BS/MD program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician before joining industry.
Recent Insider Transactions • May 18Insider recently sold US$616k worth of stockOn the 16th of May, Andrea Loewen-Rodriguez sold around 7k shares on-market at roughly US$86.01 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$808k. Insiders have been net sellers, collectively disposing of US$4.6m more than they bought in the last 12 months.
Major Estimate Revision • May 17Consensus revenue estimates increase by 27%, EPS downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$42.5m to US$53.9m. EPS estimate fell from -US$8.95 to -US$10.28 per share. Pharmaceuticals industry in the US expected to see average net income decline 7.8% next year. Consensus price target broadly unchanged at US$113. Share price fell 19% to US$85.02 over the past week.
Breakeven Date Change • May 12Forecast to breakeven in 2025The 9 analysts covering Reata Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 26% per year to 2024. The company is expected to make a profit of US$190.1m in 2025. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Reported Earnings • May 10First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$3.14 loss per share (further deteriorated from US$2.03 loss in 1Q 2022). Net loss: US$116.1m (loss widened 57% from 1Q 2022). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Mar 20Executive VP & Chief Commercial Officer recently sold US$808k worth of stockOn the 13th of March, Dawn Bir sold around 9k shares on-market at roughly US$86.77 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.9m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 16Executive VP & Chief Commercial Officer recently sold US$630k worth of stockOn the 7th of March, Dawn Bir sold around 7k shares on-market at roughly US$90.03 per share. This transaction amounted to 92% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.1m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Mar 09Executive VP & Chief Innovation Officer exercised options and sold US$7.7m worth of stockOn the 2nd of March, Colin Meyer exercised options to acquire 89k shares at no cost and sold these for an average price of US$86.69 per share. This trade did not impact their existing holding. Since June 2022, Colin's direct individual holding has increased from 93.49k shares to 101.33k. Company insiders have collectively sold US$17m more than they bought, via options and on-market transactions in the last 12 months.
Breakeven Date Change • Mar 03Forecast to breakeven in 2025The 9 analysts covering Reata Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 26% per year to 2024. The company is expected to make a profit of US$104.6m in 2025. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 03Consensus revenue estimates increase by 18%, EPS downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$26.1m to US$30.8m. EPS estimate fell from -US$8.43 to -US$9.00 per share. Pharmaceuticals industry in the US expected to see average net income growth of 5.6% next year. Consensus price target up from US$62.40 to US$111. Share price rose 95% to US$86.81 over the past week.
Price Target Changed • Mar 01Price target increased by 75% to US$104Up from US$59.50, the current price target is an average from 10 analysts. New target price is 12% above last closing price of US$93.17. Stock is up 184% over the past year. The company is forecast to post a net loss per share of US$8.65 next year compared to a net loss per share of US$8.54 last year.
Reported Earnings • Feb 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$8.54 loss per share (further deteriorated from US$8.19 loss in FY 2021). Net loss: US$311.9m (loss widened 4.9% from FY 2021). Products in clinical trials Phase I: 1 Phase III: 3 Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 1.3%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target increased to US$59.50Up from US$54.20, the current price target is an average from 10 analysts. New target price is 43% above last closing price of US$41.67. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$8.43 next year compared to a net loss per share of US$8.19 last year.
Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$3.01m to US$2.59m. EPS estimate unchanged at -US$8.43 per share. Pharmaceuticals industry in the US expected to see average net income growth of 4.6% next year. Consensus price target up from US$54.20 to US$59.50. Share price rose 3.4% to US$41.67 over the past week.
Price Target Changed • Nov 11Price target increased to US$59.50Up from US$54.20, the current price target is an average from 10 analysts. New target price is 55% above last closing price of US$38.27. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$8.43 next year compared to a net loss per share of US$8.19 last year.
Reported Earnings • Nov 10Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: US$2.16 loss per share (further deteriorated from US$1.97 loss in 3Q 2021). Net loss: US$79.0m (loss widened 10.0% from 3Q 2021). Revenue missed analyst estimates by 26%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 13FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drugReata Pharmaceuticals (NASDAQ:RETA) on Thursday said the U.S. FDA had informed the company that it was not planning to hold an advisory committee meeting for the review of its new drug application for its Friedreich's ataxia treatment. The company is developing an investigational activator called omaveloxolone for the treatment of the rare, genetic neuromuscular disorder. The treatment has previously received U.S. FDA orphan drug, fast track and rare pediatric disease designations. Class A shares of RETA earlier closed +2.6% at $25.05.
Major Estimate Revision • Aug 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$4.26m to US$3.18m. EPS estimate unchanged at -US$8.43 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.6% next year. Consensus price target down from US$57.11 to US$50.67. Share price fell 14% to US$20.61 over the past week.
Price Target Changed • Aug 10Price target decreased to US$50.67Down from US$57.11, the current price target is an average from 5 analysts. New target price is 135% above last closing price of US$21.56. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$8.45 next year compared to a net loss per share of US$8.19 last year.
Reported Earnings • Aug 08Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: US$2.02 loss per share (down from US$2.00 loss in 2Q 2021). Revenue: US$762.0k (down 66% from 2Q 2021). Net loss: US$73.6m (loss widened 1.2% from 2Q 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 199%, compared to a 14% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Aug 05Reata Pharmaceuticals Q2 2022 Earnings PreviewReata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$1.97 (-49.2% Y/Y) and the consensus Revenue Estimate is $1.46M (-34.2% Y/Y). Over the last 2 years, RETA has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
Major Estimate Revision • May 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$5.27m to US$4.74m. EPS estimate increased from -US$8.95 to -US$8.44 per share. Pharmaceuticals industry in the US expected to see average net income growth of 12% next year. Consensus price target broadly unchanged at US$59.00. Share price rose 14% to US$27.84 over the past week.
Reported Earnings • May 10First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: US$2.03 loss per share (down from US$1.86 loss in 1Q 2021). Revenue: US$914.0k (down 3.2% from 1Q 2021). Net loss: US$73.8m (loss widened 9.5% from 1Q 2021). Revenue missed analyst estimates by 41%. Earnings per share (EPS) exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 54%, compared to a 6.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Apr 27Price target increased to US$59.67Up from US$53.33, the current price target is an average from 8 analysts. New target price is 130% above last closing price of US$25.91. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$8.95 next year compared to a net loss per share of US$8.19 last year.
Seeking Alpha • Mar 28Reata Pharmaceuticals: Once Beaten, Twice ShyReata's lead asset, bardoxolone, is beyond salvage. Omaveloxolone, the second asset, may be producing hope in some investors. However, I would be very careful about what Reata tells us about what the FDA told Reata.
Price Target Changed • Mar 24Price target increased to US$62.75Up from US$53.67, the current price target is an average from 7 analysts. New target price is 69% above last closing price of US$37.09. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$8.91 next year compared to a net loss per share of US$8.19 last year.
Reported Earnings • Mar 02Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$8.19 loss per share (down from US$7.35 loss in FY 2020). Revenue: US$11.5m (up 27% from FY 2020). Net loss: US$297.4m (loss widened 20% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 1.1%. Over the next year, revenue is expected to shrink by 48% compared to a 21% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Mar 01No longer forecast to breakevenThe 7 analysts covering Reata Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$65.4m in 2024. New consensus forecast suggests the company will make a loss of US$378.9m in 2024.
Seeking Alpha • Dec 31Reata's Advisory Committee Hiccup Ruins Its Future ProspectsReata's bardoxolone was unanimously turned down by an advisory committee panel, voting 13-0 against the drug. Management's characterisation of FDA interactions raises concerns about the company. I will stay cautious around this ticker.